The ASCC2 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung carcinoma epithelial cell line, featuring targeted disruption of the ASCC2 gene. This loss-of-function model is generated using CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous knockout pool suitable for studying the cellular consequences of ASCC2 ablation. The polyclonal format preserves diverse genetic backgrounds, mimicking natural biological variability and enabling robust functional analyses in DNA repair and transcriptional regulation research.
The A-549 host cell line originates from alveolar basal epithelial cells isolated from a 58-year-old Caucasian male diagnosed with lung carcinoma. These cells serve as a widely employed model for studying lung adenocarcinoma biology, drug responses, and epithelial cell physiology. The A-549 line exhibits hallmark characteristics of epithelial cells, including substrate attachment and expression of lung-specific markers, providing a physiologically relevant context for investigating ASCC2-dependent processes in cancer and DNA damage responses.
ASCC2 encodes a subunit of the ASC-1 complex, a transcriptional coactivator for nuclear receptors that also plays an essential role in the repair of DNA alkylation damage by resolving interstrand crosslinks. Within this complex, ASCC2 interacts directly with ASCC3 and TRIP4, coordinating the assembly and activity of the ASC-1 complex at sites of DNA damage and at target gene promoters. Upstream, ASCC2 expression and function are regulated by androgen receptor signaling, DNA damage signaling cascades, and the p53 tumor suppressor, integrating hormonal and genotoxic stress inputs. Downstream, ASCC2-mediated transcriptional activation promotes the expression of DNA repair genes and cell survival factors, while its loss perturbs both DNA repair efficiency and transcriptional regulation, highlighting its role as a critical node in the DNA damage response and hormone-driven transcription.
In the A-549 lung adenocarcinoma background, ASCC2 knockout models the functional interplay between transcriptional regulation and DNA repair within an oncogenic context. This cell line harbors mutations in signaling pathways often dysregulated in lung cancer, providing a platform to dissect how ASCC2 loss influences cellular responses to chemotherapeutic agents that induce DNA alkylation damage, such as temozolomide or cisplatin. Moreover, because A-549 cells express androgen receptor and p53 pathway components, the knockout enables investigation of ASCC2??s role downstream of these regulators in mediating survival, proliferation, and DNA damage tolerance, potentially revealing therapeutic vulnerabilities in resistant tumors.
Researchers can leverage this polyclonal knockout model in a wide range of assays, including Western blotting to confirm ASCC2 protein depletion, comet assays to quantify DNA strand break accumulation, and cell viability assays to assess sensitivity to DNA-damaging agents. RT-qPCR and immunofluorescence track transcriptional changes and protein localization alterations, while colony formation and apoptosis assays evaluate long-term survival and cell death. These tools support DNA repair, transcription regulation, cancer biology, and drug resistance investigations. For technical specifications or ordering, contact Ascent Research.
